MAGEH1 and ancylostomiasis: For this reason, we believe that APR-1 is now the major vaccine antigen from the adult stage of the parasite, and as such, Na-APR-1 should undergo process development and enter into Phase I clinical trials as a vaccine for human hookworm infection.